Polyrizon Ltd. (PLRZ)

$1.55 -0.09 (-5.49%)
Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 1,429,814
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts N/A
Price Target N/A

Company Profile

Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It also develops PL-14, a nasal allergies blocker; PL-15 for COVID-19; and PL-16 for influenza blockers. Polyrizon Ltd. was incorp...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 9 374 0120
Address:
5 Ha-Tidhar Street, Ra'anana, Israel
patrick1956
patrick1956 Feb. 4 at 7:06 PM
$PLRZ ....no reason for this to drop...small volume...ppl playing games to get you to sell...they made a good investment with $$$$ they had..otherwise no reason for this to drop...imo
0 · Reply
Swats20
Swats20 Feb. 4 at 5:04 PM
$PLRZ what’s happening??
1 · Reply
theflynews
theflynews Feb. 4 at 4:48 PM
Biotech Alert: Searches spiking for these stocks today - $PLRZ - https://legacy.thefly.com/permalinks/entry.php/id4284991
0 · Reply
Swats20
Swats20 Feb. 4 at 3:46 PM
$PLRZ
0 · Reply
raulaa
raulaa Feb. 4 at 2:14 PM
$PLRZ lets fly
0 · Reply
Tbirdyguy
Tbirdyguy Feb. 4 at 1:58 PM
$PLRZ
0 · Reply
raulaa
raulaa Feb. 4 at 1:50 PM
$PLRZ
0 · Reply
raulaa
raulaa Feb. 4 at 1:49 PM
$PLRZ Polyrizon (PLRZ), a pre-clinical biotechnology firm, has signed a memorandum of understanding (MOU) to acquire a 51% stake in Arrow Aviation, a global private aviation company.
0 · Reply
Rampageusa
Rampageusa Feb. 4 at 12:57 PM
$PLRZ 17.8 pre market, we should go 20+, 24 is my pt…
0 · Reply
fivehundredpercent
fivehundredpercent Feb. 4 at 12:55 PM
$PLRZ all the sellers got absorbed expect this to move higher regular session
1 · Reply
Latest News on PLRZ
Polyrizon Intends to Acquire 51% Stake in Global Private Aviation Company

Feb 4, 2026, 7:12 AM EST - 7 hours ago

Polyrizon Intends to Acquire 51% Stake in Global Private Aviation Company

Polyrizon Advances Regulatory Path with Initiation of Usability Study Program for NASARIX™ Allergy Blocker

Jan 22, 2026, 9:25 AM EST - 13 days ago

Polyrizon Advances Regulatory Path with Initiation of Usability Study Program for NASARIX™ Allergy Blocker

Polyrizon to Explore Revenue-Generating Investment Opportunities in High-Growth Sectors, Leveraging Strong Cash Position and Debt-Free Balance Sheet

Jan 13, 2026, 8:39 AM EST - 22 days ago

Polyrizon to Explore Revenue-Generating Investment Opportunities in High-Growth Sectors, Leveraging Strong Cash Position and Debt-Free Balance Sheet

Polyrizon Completes Branding Process for PL-14 Allergy Blocker with Brand Name NASARIX™

Jan 8, 2026, 8:45 AM EST - 27 days ago

Polyrizon Completes Branding Process for PL-14 Allergy Blocker with Brand Name NASARIX™

Polyrizon Announces New Pre-Clinical Results: PL-14 Demonstrates Significant Allergen-Blocking Performance Compared to a Standard Comparator

Jan 5, 2026, 9:07 AM EST - 4 weeks ago

Polyrizon Announces New Pre-Clinical Results: PL-14 Demonstrates Significant Allergen-Blocking Performance Compared to a Standard Comparator

As Flu Surge Continues, Polyrizon's Nasal Spray Emerges as Potential Extra Shield Solution for Both Vaccinated and Unvaccinated

Jan 2, 2026, 8:30 AM EST - 4 weeks ago

As Flu Surge Continues, Polyrizon's Nasal Spray Emerges as Potential Extra Shield Solution for Both Vaccinated and Unvaccinated

Polyrizon to Explore Revenue-Generating Real Asset Opportunities, Leveraging Strong Cash Position and Debt-Free Balance Sheet

Dec 29, 2025, 7:20 AM EST - 5 weeks ago

Polyrizon to Explore Revenue-Generating Real Asset Opportunities, Leveraging Strong Cash Position and Debt-Free Balance Sheet

Polyrizon Submits Pre-Request for Designation to FDA for PL-16 Viral Blocker Designed to Reduce the Exposure to Influenza and Cold Viruses

Dec 19, 2025, 8:20 AM EST - 6 weeks ago

Polyrizon Submits Pre-Request for Designation to FDA for PL-16 Viral Blocker Designed to Reduce the Exposure to Influenza and Cold Viruses

Polyrizon Announces Promising Permeation Kinetics Supporting Advancement of Its Intranasal Naloxone Hydrogel Program

Dec 11, 2025, 8:15 AM EST - 7 weeks ago

Polyrizon Announces Promising Permeation Kinetics Supporting Advancement of Its Intranasal Naloxone Hydrogel Program

Polyrizon Completes FDA Pre-Submission Meeting for PL-14 Allergy Blocker Nasal Spray

Dec 8, 2025, 8:55 AM EST - 2 months ago

Polyrizon Completes FDA Pre-Submission Meeting for PL-14 Allergy Blocker Nasal Spray

From Lab to Global Impact: Polyrizon's Journey to Potentially Redefining Next-Generation Nasal Protection

Dec 4, 2025, 7:32 AM EST - 2 months ago

From Lab to Global Impact: Polyrizon's Journey to Potentially Redefining Next-Generation Nasal Protection

Polyrizon Reports Positive Mucoadhesion Results for Intranasal Naloxone Hydrogel Compared to Marketed Intranasal Naloxone product

Dec 3, 2025, 9:28 AM EST - 2 months ago

Polyrizon Reports Positive Mucoadhesion Results for Intranasal Naloxone Hydrogel Compared to Marketed Intranasal Naloxone product

Polyrizon Announces Successful Completion of Key Manufacturing Upscaling Milestone for Its Nasal Spray Platform

Dec 2, 2025, 7:55 AM EST - 2 months ago

Polyrizon Announces Successful Completion of Key Manufacturing Upscaling Milestone for Its Nasal Spray Platform

Polyrizon Demonstrates Reversible Broad-Spectrum Viral Blocking by Its Intranasal Barrier-Forming Formulation

Nov 6, 2025, 8:55 AM EST - 3 months ago

Polyrizon Demonstrates Reversible Broad-Spectrum Viral Blocking by Its Intranasal Barrier-Forming Formulation

Polyrizon Announces Positive Pre-Clinical Results: PL-14 Demonstrates Encouraging Allergen-Blocking Efficacy

Oct 6, 2025, 8:21 AM EDT - 4 months ago

Polyrizon Announces Positive Pre-Clinical Results: PL-14 Demonstrates Encouraging Allergen-Blocking Efficacy

Polyrizon Submits Pre-Sub Package to the FDA for PL-14 Allergy Blocker

Sep 19, 2025, 8:15 AM EDT - 4 months ago

Polyrizon Submits Pre-Sub Package to the FDA for PL-14 Allergy Blocker

Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study

Sep 12, 2025, 7:26 AM EDT - 5 months ago

Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study

Polyrizon Regains Compliance with Nasdaq Listing Requirements

Aug 14, 2025, 8:14 AM EDT - 6 months ago

Polyrizon Regains Compliance with Nasdaq Listing Requirements

Polyrizon Retains Nasdaq Listing Following Hearings Panel

Jul 15, 2025, 7:55 AM EDT - 7 months ago

Polyrizon Retains Nasdaq Listing Following Hearings Panel

Polyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS Therapeutics

Jun 12, 2025, 7:32 AM EDT - 8 months ago

Polyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS Therapeutics

Polyrizon Announces Receipt of Nasdaq Delisting Notice

May 23, 2025, 4:15 PM EDT - 9 months ago

Polyrizon Announces Receipt of Nasdaq Delisting Notice

Polyrizon Emerges with Positive Preclinical Data on Nasal Protection Platform

May 21, 2025, 7:10 AM EDT - 9 months ago

Polyrizon Emerges with Positive Preclinical Data on Nasal Protection Platform

Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue Treatment

May 13, 2025, 7:45 AM EDT - 9 months ago

Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue Treatment

Polyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue Model

Apr 25, 2025, 7:37 AM EDT - 10 months ago

Polyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue Model

Polyrizon Receives Nasdaq Notification Regarding Minimum Bid Requirements

Apr 11, 2025, 4:15 PM EDT - 10 months ago

Polyrizon Receives Nasdaq Notification Regarding Minimum Bid Requirements

Polyrizon Engages Leading Branding Firm for Strategic Brand Development

Apr 2, 2025, 9:05 AM EDT - 11 months ago

Polyrizon Engages Leading Branding Firm for Strategic Brand Development

Polyrizon Ltd. Announces Closing of $17.0 Million Private Placement

Apr 1, 2025, 4:09 PM EDT - 11 months ago

Polyrizon Ltd. Announces Closing of $17.0 Million Private Placement

Polyrizon Ltd. Announces $17.0 Million Private Placement

Mar 31, 2025, 9:32 AM EDT - 11 months ago

Polyrizon Ltd. Announces $17.0 Million Private Placement

Polyrizon Structures Clinical Strategy for its Allergy Blocker Ahead of FDA Pre-Submission Meeting

Mar 27, 2025, 8:25 AM EDT - 11 months ago

Polyrizon Structures Clinical Strategy for its Allergy Blocker Ahead of FDA Pre-Submission Meeting

Polyrizon Expands Drug Delivery Innovation with Preclinical Studies for Epilepsy Rescue Treatment

Mar 25, 2025, 4:04 PM EDT - 11 months ago

Polyrizon Expands Drug Delivery Innovation with Preclinical Studies for Epilepsy Rescue Treatment

Polyrizon Signs Non– Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments

Mar 14, 2025, 8:35 AM EDT - 11 months ago

Polyrizon Signs Non– Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments

Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform

Mar 13, 2025, 7:51 AM EDT - 11 months ago

Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform

Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024

Mar 11, 2025, 4:27 PM EDT - 11 months ago

Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024

Polyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T Platform

Mar 10, 2025, 7:47 AM EDT - 11 months ago

Polyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T Platform

Polyrizon Announces Filing of Divisional Patent Application for Its Innovative Trap & Target™ (T&T) Intranasal Drug Delivery Platform

Jan 30, 2025, 5:55 AM EST - 1 year ago

Polyrizon Announces Filing of Divisional Patent Application for Its Innovative Trap & Target™ (T&T) Intranasal Drug Delivery Platform

Polyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial

Jan 23, 2025, 6:40 AM EST - 1 year ago

Polyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial

Polyrizon Announces Publication of U.S. National Patent Application for Its Innovative Hydrogel Nasal Technologies

Dec 30, 2024, 6:25 AM EST - 1 year ago

Polyrizon Announces Publication of U.S. National Patent Application for Its Innovative Hydrogel Nasal Technologies

Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs

Dec 19, 2024, 7:22 AM EST - 1 year ago

Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs

Polyrizon's Moving Forward with Expected 2025 Clinical Trial - Entered Manufacturing Agreement for its PL-14 Allergy Blocker

Dec 18, 2024, 6:25 AM EST - 1 year ago

Polyrizon's Moving Forward with Expected 2025 Clinical Trial - Entered Manufacturing Agreement for its PL-14 Allergy Blocker

Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance

Dec 13, 2024, 6:25 AM EST - 1 year ago

Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance

Polyrizon Enters into GMP Manufacturing Agreement for CTM Supply of its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial

Dec 2, 2024, 8:02 AM EST - 1 year ago

Polyrizon Enters into GMP Manufacturing Agreement for CTM Supply of its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial

Aegis Capital Corp. Acted as Sole Bookrunner on a $4.2 Million (IPO) Initial Public Offering for Polyrizon Ltd. (NASDAQ: PLRZ)

Oct 30, 2024, 1:50 PM EDT - 1 year ago

Aegis Capital Corp. Acted as Sole Bookrunner on a $4.2 Million (IPO) Initial Public Offering for Polyrizon Ltd. (NASDAQ: PLRZ)

Polyrizon Announces Closing of $4.2 Million Initial Public Offering

Oct 30, 2024, 10:28 AM EDT - 1 year ago

Polyrizon Announces Closing of $4.2 Million Initial Public Offering

Polyrizon Announces Pricing of $4.2 Million Initial Public Offering and Listing on the Nasdaq Capital Market Under New Ticker “PLRZ”

Oct 28, 2024, 7:02 PM EDT - 1 year ago

Polyrizon Announces Pricing of $4.2 Million Initial Public Offering and Listing on the Nasdaq Capital Market Under New Ticker “PLRZ”

patrick1956
patrick1956 Feb. 4 at 7:06 PM
$PLRZ ....no reason for this to drop...small volume...ppl playing games to get you to sell...they made a good investment with $$$$ they had..otherwise no reason for this to drop...imo
0 · Reply
Swats20
Swats20 Feb. 4 at 5:04 PM
$PLRZ what’s happening??
1 · Reply
theflynews
theflynews Feb. 4 at 4:48 PM
Biotech Alert: Searches spiking for these stocks today - $PLRZ - https://legacy.thefly.com/permalinks/entry.php/id4284991
0 · Reply
Swats20
Swats20 Feb. 4 at 3:46 PM
$PLRZ
0 · Reply
raulaa
raulaa Feb. 4 at 2:14 PM
$PLRZ lets fly
0 · Reply
Tbirdyguy
Tbirdyguy Feb. 4 at 1:58 PM
$PLRZ
0 · Reply
raulaa
raulaa Feb. 4 at 1:50 PM
$PLRZ
0 · Reply
raulaa
raulaa Feb. 4 at 1:49 PM
$PLRZ Polyrizon (PLRZ), a pre-clinical biotechnology firm, has signed a memorandum of understanding (MOU) to acquire a 51% stake in Arrow Aviation, a global private aviation company.
0 · Reply
Rampageusa
Rampageusa Feb. 4 at 12:57 PM
$PLRZ 17.8 pre market, we should go 20+, 24 is my pt…
0 · Reply
fivehundredpercent
fivehundredpercent Feb. 4 at 12:55 PM
$PLRZ all the sellers got absorbed expect this to move higher regular session
1 · Reply
fivehundredpercent
fivehundredpercent Feb. 4 at 12:20 PM
$PLRZ news wow
0 · Reply
raulaa
raulaa Feb. 4 at 12:18 PM
$PLRZ pre market going crazy
0 · Reply
cupandhandleguy
cupandhandleguy Feb. 3 at 7:47 PM
$PLRZ looks like a launch pad
1 · Reply
patrick1956
patrick1956 Feb. 3 at 6:48 PM
$PLRZ ...hearing something in news front coming out in next few days...reason accumulation is being done gradually...get your shares and wait...imo
1 · Reply
tiger8464
tiger8464 Feb. 3 at 6:12 PM
$PLRZ Buy .. setting up for breakout
0 · Reply
Tbirdyguy
Tbirdyguy Feb. 3 at 4:33 PM
$PLRZ volume is gone, for now, it'll be back. Pl16 should be getting regulatory clarity any day now. PL14 has plenty important steps left but timeline might be longer for this one. My money is Pl16 bringing at least some volume back.
0 · Reply
LegionOfBoom
LegionOfBoom Feb. 3 at 3:26 PM
$PLRZ Very strong this morning
0 · Reply
Godwins26
Godwins26 Feb. 3 at 3:01 PM
Watchlist 🚀 $INLF moves fast with small buys🚀 $AMC $FIT $EPLW $PLRZ
0 · Reply
Rampageusa
Rampageusa Feb. 3 at 1:02 PM
$PLRZ need another 30% jump to 24$. Lets do it..
2 · Reply
Swats20
Swats20 Feb. 3 at 11:53 AM
$PLRZ any guesses for today?
0 · Reply
Godwins26
Godwins26 Feb. 3 at 4:24 AM
Watchlist 😊 $INLF looks like it's next to go up 5000% $TCGL $ELPW $ANL $PLRZ
0 · Reply
Stock_Catcher
Stock_Catcher Feb. 3 at 2:20 AM
Treasure Tuesday Watchlist Pt.7 $PLRZ $INDO $SATL $ABAT $AZI Let's Find a Big Runner Tomorrow
0 · Reply